ERK1/2 acts as a switch between necrotic and apoptotic cell death in ether phospholipid edelfosine-treated glioblastoma cells

Pharmacological Research

Volumn 95-96, Issue , 2015, Pages 2-11

  Melo Lima, Sara ^a,b   Lopes, Maria C ^b,c   Mollinedo, Faustino ^a,d  

^a Centro de Investigacion del Cancer   (Spain)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Alkylphospholipid analog; Apoptosis; Edelfosine; ERK1 2; Glioblastoma; Necroptosis

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CASPASE 3; CASPASE 8; CASPASE 9; EDELFOSINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN BCL XL; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RECEPTOR INTERACTING SERINE THREONINE PROTEIN KINASE 1; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; 1,3 BUTADIENE DERIVATIVE; ENZYME INHIBITOR; ETHER PHOSPHOLIPID; NITRILE; RIPK1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; NECROPTOSIS; NERVE CELL NECROSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; BIOSYNTHESIS; BRAIN NEOPLASMS; CULTURE TECHNIQUE; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GLIOBLASTOMA; NECROSIS; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; BUTADIENES; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME INHIBITORS; FLOW CYTOMETRY; GLIOBLASTOMA; HUMANS; MAP KINASE SIGNALING SYSTEM; MICROSCOPY, FLUORESCENCE; NECROSIS; NITRILES; PHOSPHOLIPID ETHERS; PHOSPHORYLATION; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES;

EID: 84925596605     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.02.007     Document Type: Article

References (63)

1. D.N. Louis, H. Ohgaki, O.D. Wiestler, W.K. Cavenee, P.C. Burger, and A. Jouvet The 2007 WHO classification of tumours of the central nervous system Acta Neuropathol 114 2007 97 109
2. Z. Lwin, D. Macfadden, A. Al-Zahrani, E. Atenafu, B.A. Miller, and A. Sahgal Glioblastoma management in the temozolomide era: have we improved outcome? J Neurooncol 115 2013 303 310
3. A. Omuro, and L.M. DeAngelis Glioblastoma and other malignant gliomas: a clinical review JAMA 310 2013 1842 1850
4. O.O. Kanu, B. Hughes, C. Di, N. Lin, J. Fu, and D.D. Bigner Glioblastoma multiforme oncogenomics and signaling pathways Clin Med Oncol 3 2009 39 52
5. D. Kogel, S. Fulda, and M. Mittelbronn Therapeutic exploitation of apoptosis and autophagy for glioblastoma Anticancer Agents Med Chem 10 2010 438 449
6. S.M. Raza, G.N. Fuller, C.H. Rhee, S. Huang, K. Hess, and W. Zhang Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis Clin Cancer Res 10 2004 212 221
7. D.N. Louis Molecular pathology of malignant gliomas Annu Rev Pathol 1 2006 97 117
8. T. Homma, T. Fukushima, S. Vaccarella, Y. Yonekawa, P.L. Di Patre, and S. Franceschi Correlation among pathology, genotype, and patient outcomes in glioblastoma J Neuropathol Exp Neurol 65 2006 846 854
9. C.R. Miller, C.P. Dunham, B.W. Scheithauer, and A. Perry Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas J Clin Oncol 24 2006 5419 5426
10. S.M. Raza, F.F. Lang, B.B. Aggarwal, G.N. Fuller, D.M. Wildrick, and R. Sawaya Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis Neurosurgery 51 2002 2 12 discussion 12-3
11. S. Nagai, K. Washiyama, M. Kurimoto, A. Takaku, S. Endo, and T. Kumanishi Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma J Neurosurg 96 2002 909 917
12. G. Choe, J.K. Park, L. Jouben-Steele, T.J. Kremen, L.M. Liau, and H.V. Vinters Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype Clin Cancer Res 8 2002 2894 2901
13. C.Y. Thomas, M. Chouinard, M. Cox, S. Parsons, M. Stallings-Mann, and R. Garcia Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells Int J Cancer 104 2003 19 27
14. M. Failly, S. Korur, V. Egler, J.L. Boulay, M.M. Lino, and R. Imber Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells Mol Cancer Ther 6 2007 773 781
15. C. Nakanishi, and M. Toi Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs Nat Rev Cancer 5 2005 297 309
16. G.P. Atkinson, S.E. Nozell, and E.T. Benveniste NF-kappaB and STAT3 signaling in glioma: targets for future therapies Expert Rev Neurother 10 2010 575 586
17. G. Minniti, R. Muni, G. Lanzetta, P. Marchetti, and R.M. Enrici Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents Anticancer Res 29 2009 5171 5184
18. F. Ohka, A. Natsume, and T. Wakabayashi Current trends in targeted therapies for glioblastoma multiforme Neurol Res Int 2012 2012 878425
19. T.A. Juratli, G. Schackert, and D. Krex Current status of local therapy in malignant gliomas - a clinical review of three selected approaches Pharmacol Ther 139 2013 341 358
20. L. Galluzzi, I. Vitale, J.M. Abrams, E.S. Alnemri, E.H. Baehrecke, and M.V. Blagosklonny Molecular definitions of cell death subroutines: recommendations of the nomenclature committee on cell death 2012 Cell Death Differ 19 2012 107 120
21. O. Kepp, L. Galluzzi, M. Lipinski, J. Yuan, and G. Kroemer Cell death assays for drug discovery Nat Rev Drug Discov 10 2011 221 237
22. P. Vandenabeele, L. Galluzzi, T. Vanden Berghe, and G. Kroemer Molecular mechanisms of necroptosis: an ordered cellular explosion Nat Rev Mol Cell Biol 11 2010 700 714
23. D.E. Christofferson, and J. Yuan Necroptosis as an alternative form of programmed cell death Curr Opin Cell Biol 22 2010 263 268
24. M. Leist, and P. Nicotera The shape of cell death Biochem Biophys Res Commun 236 1997 1 9
25. G. Reynes, V. Vila, M. Martin, A. Parada, T. Fleitas, and E. Reganon Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma J Neurooncol 102 2011 35 41
26. J. Guo, S. Shinriki, Y. Su, T. Nakamura, M. Hayashi, and Y. Tsuda Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy Oncotarget 5 2014 6353 6364
27. 3 (edelfosine), a proapoptotic agent in tumor cells Curr Drug Metab 3 2002 491 525
28. 3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor Curr Med Chem 11 2004 3163 3184
29. F. Mollinedo Editorial: antitumor alkylphospholipid analogs: a promising and growing family of synthetic cell membrane-targeting molecules for cancer treatment Anticancer Agents Med Chem 14 2014 495 498
30. 3 Biochem Biophys Res Commun 192 1993 603 609
31. L Cancer Res 57 1997 1320 1328
32. C. Gajate, R.I. Fonteriz, C. Cabaner, G. Alvarez-Noves, Y. Alvarez-Rodriguez, and M. Modolell Intracellular triggering of Fas, independently of Fasl, as a new mechanism of antitumor ether lipid-induced apoptosis Int J Cancer 85 2000 674 682
33. 3-induced apoptosis of human leukemic cells Int J Cancer 86 2000 208 218
34. F. Mollinedo, and C. Gajate Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy Drug Resist Updat 9 2006 51 73
35. C. Gajate, and F. Mollinedo Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts Blood 109 2007 711 719
36. T. Nieto-Miguel, R.I. Fonteriz, L. Vay, C. Gajate, S. Lopez-Hernandez, and F. Mollinedo Endoplasmic reticulum stress in the proapoptotic action of edelfosine in solid tumor cells Cancer Res 67 2007 10368 10378
37. F. Mollinedo, and C. Gajate Lipid rafts and clusters of apoptotic signaling molecule-enriched rafts in cancer therapy Future Oncol 6 2010 811 821
38. F. Mollinedo, J. de la Iglesia-Vicente, C. Gajate, A. Estella-Hermoso de Mendoza, J.A. Villa-Pulgarin, and M.A. Campanero Lipid raft-targeted therapy in multiple myeloma Oncogene 29 2010 3748 3757
39. F. Mollinedo, J. de la Iglesia-Vicente, C. Gajate, A. Estella-Hermoso de Mendoza, J.A. Villa-Pulgarin, and M. de Frias In vitro and in vivo selective antitumor activity of edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts Clin Cancer Res 16 2010 2046 2054
40. F. Mollinedo, M. Fernandez, V. Hornillos, J. Delgado, F. Amat-Guerri, and A.U. Acuna Involvement of lipid rafts in the localization and dysfunction effect of the antitumor ether phospholipid edelfosine in mitochondria Cell Death Dis 2 2011 e158
41. C. Gajate, M. Matos-da-Silva, E.L. Dakir, R.I. Fonteriz, J. Alvarez, and F. Mollinedo Antitumor alkyl-lysophospholipid analog edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum Oncogene 31 2012 2627 2639
42. C. Gajate, and F. Mollinedo Lipid rafts, endoplasmic reticulum and mitochondria in the antitumor action of the alkylphospholipid analog edelfosine Anticancer Agents Med Chem 14 2014 509 527
43. S. Melo-Lima, C. Gajate, and F. Mollinedo Triggers and signaling cross-talk controlling cell death commitment Cell Cycle 14 2015 465 466
44. S. Melo-Lima, M. Celeste Lopes, and F. Mollinedo Necroptosis is associated with low procaspase-8 and active ripk1 and -3 in human glioma cells Oncoscience 1 2014 649 664
45. M.F. Favata, K.Y. Horiuchi, E.J. Manos, A.J. Daulerio, D.A. Stradley, and W.S. Feeser Identification of a novel inhibitor of mitogen-activated protein kinase kinase J Biol Chem 273 1998 18623 18632
46. N. Engedal, and H.K. Blomhoff Combined action of Erk and NF-kappa B mediates the protective effect of phorbol ester on Fas-induced apoptosis in Jurkat cells J Biol Chem 278 2003 10934 10941
47. M. Marzec, M. Kasprzycka, X. Liu, P.N. Raghunath, P. Wlodarski, and M.A. Wasik Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf Oncogene 26 2007 813 821
48. A. Glassmann, J. Winter, D. Kraus, N. Veit, and R. Probstmeier Pharmacological suppression of the RAS/MAPK pathway in thyroid carcinoma cells can provoke opposite effects on cell migration and proliferation: the appearance of yin-yang effects and the need of combinatorial treatments Int J Oncol 45 2014 2587 2595
49. X. Ma, Q. Wang, Y. Liu, Y. Chen, L. Zhang, and M. Jiang Inhibition of tumor growth by U0126 is associated with induction of interferon-gamma production Int J Cancer 136 2015 771 783
50. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J Immunol Methods 65 1983 55 63
51. N. Takahashi, L. Duprez, S. Grootjans, A. Cauwels, W. Nerinckx, and J.B. DuHadaway Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models Cell Death Dis 3 2012 e437
52. X. Wu, H. Chen, B. Parker, E. Rubin, T. Zhu, and J.S. Lee HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition Cancer Res 66 2006 9527 9534
53. 2-IIA abrogates TNFalpha-induced apoptosis in human astroglioma cells: crucial role of ERK Biochim Biophys Acta 1793 2009 1837 1847
54. M. Li, S.S. Ng, J. Wang, L. Lai, S.Y. Leung, and M. Franco EFA6A enhances glioma cell invasion through ADP ribosylation factor 6/extracellular signal-regulated kinase signaling Cancer Res 66 2006 1583 1590
55. C.C. Su, Y.P. Lin, Y.J. Cheng, J.Y. Huang, W.J. Chuang, and Y.S. Shan Phosphatidylinositol 3-kinase/AKT activation by integrin-tumor matrix interaction suppresses Fas-mediated apoptosis in T cells J Immunol 179 2007 4589 4597
56. Y. Lin, A. Devin, Y. Rodriguez, and Z.G. Liu Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis Genes Dev 13 1999 2514 2526
57. D. Yin, H. Zhou, T. Kumagai, G. Liu, J.M. Ong, and K.L. Black Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM) Oncogene 24 2005 344 354
58. D. Yin, D. Xie, S. Sakajiri, C.W. Miller, H. Zhu, and M.L. Popoviciu DLK1: increased expression in gliomas and associated with oncogenic activities Oncogene 25 2006 1852 1861
59. C. Rebe, S. Cathelin, S. Launay, R. Filomenko, L. Prevotat, and C. L'Ollivier Caspase-8 prevents sustained activation of NF-kappaB in monocytes undergoing macrophagic differentiation Blood 109 2007 1442 1450
60. H. Zhang, and F. Burrows Targeting multiple signal transduction pathways through inhibition of Hsp90 J Mol Med 82 2004 488 499
61. G.V. Georgakis, Y. Li, G.Z. Rassidakis, H. Martinez-Valdez, L.J. Medeiros, and A. Younes Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death Clin Cancer Res 12 2006 584 590
62. C. Fearns, Q. Pan, J.C. Mathison, and T.H. Chuang Triad3A regulates ubiquitination and proteasomal degradation of RIP1 following disruption of Hsp90 binding J Biol Chem 281 2006 34592 34600
63. H. Zhu, S. Woolfenden, R.T. Bronson, Z.M. Jaffer, S. Barluenga, and N. Winssinger The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme Mol Cancer Ther 9 2010 2618 2626